The clinicopathological characteristics of the 350 metastatic or unresectable NSCLC patients from the Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) cohort who received anti PD-1/PD-L1 monotherapy (n=329) or a combination of anti-CTLA-4 and anti-PD-1/PD-L1 immunotherapies (n=21) is shown in Table 1. Here, PDCD1 is linked to non-small cell lung carcinoma.